Compare · AAON vs TMO
AAON vs TMO
Side-by-side comparison of AAON Inc. (AAON) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AAON and TMO operate in Industrial Machinery/Components (Industrials), so they compete in similar markets.
- TMO is the larger of the two at $232.67B, about 35.5x AAON ($6.55B).
- Over the past year, AAON is down 4.9% and TMO is up 28.2% - TMO leads by 33.1 points.
- Both names hit the wire about 8 times in the past 4 weeks.
- TMO has more recent analyst coverage (25 ratings vs 12 for AAON).
- Company
- AAON Inc.
- Thermo Fisher Scientific Inc
- Price
- $79.43-1.74%
- $629.32+0.27%
- Market cap
- $6.55B
- $232.67B
- 1M return
- -26.18%
- +9.93%
- 1Y return
- -4.89%
- +28.22%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 8
- 8
- Recent ratings
- 12
- 25
AAON Inc.
AAON, Inc., together with its subsidiaries, engages in engineering, manufacturing, marketing, and selling air conditioning and heating equipment in the United States and Canada. It offers rooftop units, chillers, packaged outdoor mechanical rooms, air handling units, makeup air units, energy recovery units, condensing units, geothermal/water-source heat pumps, self-contained units, coils, and controls. The company markets and sells its products to retail, manufacturing, educational, lodging, supermarket, medical, and other commercial industries. It sells its products through a network of manufacturers' representatives and internal sales force. The company was incorporated in 1987 and is based in Tulsa, Oklahoma.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest AAON
- AAON Introduces The Aaon Group as Its New Enterprise Identity
- AAON Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- AAON Announces Quarterly Cash Dividend
- SEC Form 10-Q filed by AAON Inc.
- AAON Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- AAON Reports Record Second Quarter 2026 Results Driven by Strong Demand, Accelerating Throughput, and Improved Operating Execution
- SEC Form 3 filed by new insider Jermain Patrick John
- SEC Form 3 filed by new insider Buttermore Robert L.
- AAON Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- AAON Increases Board Size and Appoints Robert L. Buttermore III, and Patrick J. Jermain as Independent Directors
Latest TMO
- Sr. VP and Chief HR Officer Britt Lisa P. sold $7,014,093 worth of shares (11,440 units at $613.12) and exercised 11,440 shares at a strike of $418.32, decreasing direct ownership by 0.00% to 14,784 units (SEC Form 4)
- Executive Vice President Shafer Michael D exercised 25,500 shares at a strike of $370.58 and sold $15,300,000 worth of shares (25,500 units at $600.00) as part of a pre-agreed trading plan (SEC Form 4)
- Thermo Fisher Scientific Completes Sale of its Microbiology Business to Astorg
- VP & Chief Accounting Officer Holmes Joseph R. exercised 420 shares at a strike of $309.63 and sold $245,620 worth of shares (420 units at $584.81) (SEC Form 4)
- Chairman & CEO Casper Marc N exercised 275 shares at a strike of $309.63 and sold $2,862,002 worth of shares (4,883 units at $586.12) as part of a pre-agreed trading plan (SEC Form 4)
- Sr. VP and Chief HR Officer Britt Lisa P. exercised 5,850 shares at a strike of $309.63 and sold $3,393,000 worth of shares (5,850 units at $580.00), decreasing direct ownership by 0.00% to 14,784 units (SEC Form 4)
- Chairman & CEO Casper Marc N exercised 10,000 shares at a strike of $309.63 and sold $8,616,967 worth of shares (15,000 units at $574.46) as part of a pre-agreed trading plan, decreasing direct ownership by 0.00% to 123,925 units (SEC Form 4)
- Chairman & CEO Casper Marc N exercised 10,000 shares at a strike of $309.63 and sold $8,628,434 worth of shares (15,000 units at $575.23) as part of a pre-agreed trading plan, decreasing direct ownership by 0.00% to 123,925 units (SEC Form 4)
- SEC Form 10-Q filed by Thermo Fisher Scientific Inc
- President & COO Pettiti Gianluca sold $226,000 worth of shares (400 units at $565.00) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 24,651 units (SEC Form 4)